Chabiotech Co.,Ltd. (KOSDAQ:085660)

South Korea flag South Korea · Delayed Price · Currency is KRW
20,750
-800 (-3.71%)
At close: Feb 6, 2026
84.61%
Market Cap1.68T +159.2%
Revenue (ttm)1.20T +18.6%
Net Income-116.55B
EPS-1,880.73
Shares Out80.88M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume724,469
Average Volume1,395,327
Open20,750
Previous Close21,550
Day's Range20,250 - 21,250
52-Week Range9,260 - 23,950
Beta0.71
RSI62.52
Earnings DateMar 20, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 278
Stock Exchange KOSDAQ
Ticker Symbol 085660
Full Company Profile

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.

Financial Statements